Serial Number
87977676
Owner
JAZZ PHARMACEUTICALS OPERATIONS UK LIMITEDAttorney
Michael T. OlsenFiling Date
May 26, 2016
GREENWICH BIOSCIENCES Trademark
Serial Number: 87977676 • Registration: 5682224
Trademark Classes
Owner Contact Info
BUILDING 730 KENT SCIENCE PARK
SITTINGBOURNE, KENT ME9 8AG , GB
Entity Type: 24
Legal Representation
Correspondence Address
Michael T. Olsen Winthrop & Weinstine, P.A.
225 South 6th Street
Suite 3500
Minneapolis, MN 55402
UNITED STATES
Trademark Details
Filing Date
May 26, 2016
Registration Date
February 19, 2019
Published for Opposition
September 19, 2017
Cancellation Date
August 29, 2025
Goods & Services
Educational services, namely, providing and conducting classes, seminars, symposiums, conferences and workshops in the field of pharmaceutical product development of medicines, healthcare, cancer treatment and cannabinoid medicines; instruction services in the field of pharmaceutical product development of medicines, cancer treatments and cannabinoid medicines
Scientific and technological services, namely, scientific research, analysis, testing in the field of medicines, healthcare, and cancer treatment, and research and new product design services relating thereto, all not involving cannabinoid medicines; chemical analysis not involving cannabinoid medicines; chemical research not involving cannabinoid medicines; research and development in the field of medicines, healthcare, and cancer treatment, not involving cannabinoid medicines; and Scientific and technological services, namely, scientific research, analysis, testing in the field of cannabinoid medicine development, and research and new product design services relating thereto, all involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical analysis involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; chemical research involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; research and development in the field of cannabinoid medicines involving only a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols
